Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Prostate Cancer Diagnostics Market?

The market size for prostate cancer diagnostics has seen a quick expansion in recent years. It’s anticipated to rise from a value of $4.43 billion in 2024 to an impressive $5.03 billion in 2025, indicating a compound annual growth rate (CAGR) of 13.6%. Several factors contribute to the growth observed during the historic period, including an aging population, advancements in medical imaging technology, heightened awareness and screening programs, public health initiatives, and enhanced biopsy techniques.

What Growth Rate Is Forecasted for the Prostate Cancer Diagnostics Market by 2029?

Over the coming years, the prostate cancer diagnostics market is projected to experience significant expansion. By 2029, it’s forecasted that it will increase to $8.17 billion, with a compound annual growth rate (CAGR) of 12.9%. This projected growth during this period is due to factors such as the incorporation of artificial intelligence (AI), the expansion of telemedicine in cancer screening, advancements in gene profiling, patient-focused strategies, and the use of multiparametric MRI for diagnosis. Key trends during this forecast period are expected to be liquid biopsy technologies, technological progress in biomarker identification, clinical research and development, integration of digital pathology, and the emergence of multiplex biomarker assays.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12003&type=smp

Which Key Companies Are Shaping the Future of the Prostate Cancer Diagnostics Market?

Major companies operating in the prostate cancer diagnostics market include F. Hoffman-La Roche AG, Bayer AG, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Siemens Healthineers AG, Becton Dickinson and Company, Agilent Technologies Inc., Hologic Inc, Biomerieux SA, Beckman Coulter Inc., Qiagen N.V., EXACT Sciences Corporation, Diasorin S.P.A., OPKO Health Inc., Myriad Genetics Inc., Cepheid Inc, NeoGenomics Laboratories Inc., Guardant Health Inc, GRAIL Inc, Fujirebio Diagnostics Inc., Ambry Genetics Corporation, MDxHealth SA, Biocept Inc., Blue Earth Therapeutics Ltd, Exosome Diagnostics Inc., Dana-Farber Cancer Institute, Cellanyx Diagnostics Inc., A3P Biomedical AB

Which Factors Are Driving Demand in the Prostate Cancer Diagnostics Industry?

The rise in incidences of prostate cancer is anticipated to boost the expansion of the prostate cancer diagnostics market. This form of cancer originates in the prostate gland, an integral part of the reproductive system in both men and women. Diagnostics for prostate cancer enable early detection of the disease via a variety of tests such as prostate-specific antigen (PSA) testing and advanced imaging procedures. For example, the American Cancer Society (ACS), a US-based non-profit organization devoted to eradicating cancer, reported that in January 2023, around 288,300 fresh cases of prostate cancer and 34,700 deaths related to prostate cancer were expected. Hence, the escalating prevalence of prostate cancer is projected to stimulate the growth of the prostate cancer diagnostics market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12003&type=smp

How Is the Prostate Cancer Diagnostics Market Segmented by Several Divisions?

The prostate cancer diagnostics market covered in this report is segmented –

1) By Products: Instruments, Reagents And Consumables, Accessories

2) By Test Type: Preliminary Tests, Confirmatory Tests

3) By Prostate Cancer: Squamous Cell Cancer, Small Cell Carcinoma, Transitional Cell Cancer, Prostatic Adenocarcinoma, Ductal Adenocarcinoma, Small Cell Prostate Cancer, Acinar Adenocarcinoma

4) By Peer Groups: Adult, Pediatric, Geriatrics

5) By End User: Hospitals, Independent Diagnostic Laboratories, Cancer Research Institutes, Other End-Users

Subsegments:

1) By Instruments: Biopsy Instruments, Imaging Devices, Digital Rectal Examination Tools

2) By Reagents And Consumables: Diagnostic Assay Kits, Staining Reagents, Sample Collection Materials

3) By Accessories: Biopsy Guides, Specimen Handling Accessories, Calibration And Maintenance Tools

What are the Emerging Market Trends Driving the Growth of the Prostate Cancer Diagnostics Industry?

In the prostate cancer diagnostics market, a noticeable trend is the emergence of technological innovations. A variety of major firms that specialize in prostate cancer diagnostics are implementing sophisticated AI-powered diagnostic measures to maintain their market standing. This is exemplified by Qritive, a company based in Singapore that manufactures diagnostic devices, which launched QAi Prostate, a cutting-edge AI-driven tool for diagnosing prostate cancer, intended for pathologists, in March 2023. These tools employ advanced machine learning algorithms to pinpoint the prostatic adenocarcinoma region and analyze images from the whole slide of prostate core needle biopsies. Consequently, this speeds up the pathologists’ diagnostic accuracy and shortens the treatment timeline.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/prostate-cancer-diagnostics-global-market-report

Which Regions Are Driving Growth in the Prostate Cancer Diagnostics Market?

North America was the largest region in the prostate cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12003

This Report Delivers Insight On:

1. How big is the prostate cancer diagnostics market, and how is it changing globally?

2. Who are the major companies in the prostate cancer diagnostics market, and how are they performing?

3. What are the key opportunities and risks in the prostate cancer diagnostics market right now?

4. Which products or customer segments are growing the most in the prostate cancer diagnostics market?

5. What factors are helping or slowing down the growth of the prostate cancer diagnostics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model